Melanoma-associated antigen C1 (MAGEC1/CT7) is a highly tumor-restricted Cancer-Testis Antigen (CTA) frequently overexpressed in multiple myeloma, melanoma, and various epithelial cancers. Due to its negligible expression in normal tissues (except immune-privileged testis), MAGEC1 represents a high-priority target for TCR-T therapies, TCR-like antibodies, and cancer vaccines.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MAGEC1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MAGEC1 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for ELISA and binding assays. |
View MAGEC1 Products |
| Gene Delivery | MAGEC1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and antigen presentation assays. |
View MAGEC1 Products |
| Benchmark Ab | Anti-MAGEC1 Recombinant Antibody Recombinant positive control antibody for validation and IHC. |
View MAGEC1 Products |
| Validator | MAGEC1 siRNA Set For target knockdown verification and specificity controls. |
View MAGEC1 Products |
| Related Target A | MAGEC2 Homologous Cancer-Testis Antigen. Crucial for off-target and cross-reactivity screening. |
View MAGEC2 Products |
| Related Target B | MAGEA3 Co-expressed target in multiple myeloma and melanoma; ideal for multi-antigen targeting strategies. |
View MAGEA3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-family off-target reactivity screening | High-purity MAGEC2 and MAGEA3 proteins available for counter-screening panels. |
| Stable antigen presentation on APCs | Lentiviral vectors optimized for high-efficiency transduction and stable expression in target cell lines. |
| Lack of reliable positive controls | Sequence-verified clinical-grade benchmark antibodies and validated siRNA sets included. |
| Assay noise from endotoxin contamination | All recombinant proteins feature strictly controlled endotoxin levels (<1.0 EU/μg). |
Live MAGEC1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MAGEC1 therapeutics is intensifying, with major players shifting focus from traditional cancer vaccines to highly specific TCR-T (T-cell receptor engineered T-cell) therapies and TCR-like bispecific antibodies. As first-generation therapies reach the clinic, the next wave of R&D is targeting HLA-restricted MAGEC1 peptide complexes to bypass the intracellular localization barrier of native MAGEC1.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| TCR-T / TCR-like Ab | Adaptimmune, GSK, Academic Institutions | Multiple Myeloma, Melanoma | HLA-A2/MAGEC1 peptide complex specificity validation (Needs high-purity protein & stable cell lines) |
| Cancer Vaccines | BioNTech, Academic Consortia | Solid Tumors, Myeloma | Immunogenicity screening (Needs sequence-verified full-length MAGEC1 proteins) |
| mRNA Therapeutics | Moderna, CureVac | Melanoma, Non-Small Cell Lung Cancer | In vitro translation and expression validation (Needs validated siRNA and detection antibodies) |